Journal of Immunology Research

Research Article

The Differential Contribution of the Innate Immune System to a Good Pathological Response in the Breast and Axillary Lymph Nodes Induced by Neoadjuvant Chemotherapy in Women with Large and Locally Advanced Breast Cancers

Table 7

Analyses of immune cell subsets in ALNs in women with LLABCs undergoing NAC.


Immune cell subsets	Groups	ALN median (range)⁽⁴⁾	value⁽⁵⁾

CD68⁺ macrophages ()	Nonmetastatic ALNs ()	25.0 (14.8–34.0)	0.918
	Metastatic ALNs ()	29.0 (13.8–33.0)
CD163⁺ macrophages ()	Nonmetastatic ALNs ()	21.0 (16.0–29.0)	1.000
	Metastatic ALNs ()	23.0 (10.0–33.0)
CD1a⁺ DCs ()	Nonmetastatic ALNs ()	12.8 (0.8–62.0)	0.536
	Metastatic ALNs ()	23.8 (6.6–67.0)
CD66b⁺ PMNs ()	Nonmetastatic ALNs ()	5.2 (0.6–94.0)	0.837
	Metastatic ALNs ()	8.4 (1.0–163.0)

ALNs: axillary lymph nodes; LLABCs: large and locally advanced breast cancers; NAC: neoadjuvant chemotherapy; ⁽⁴⁾average percentage of positively stained cells out of all the lymphoid cells in the ALN sections examined for CD68⁺ and CD163⁺ macrophages, average cell count of positively stained cells per 400x high-power field in the ALN sections examined for CD1a⁺ DCs and CD66b⁺ PMNs; ⁽⁵⁾Mann–Whitney U test; DCs: dendritic cells; PMNs: polymorphonuclear leukocytes.